References
- Bywaters EGL. Still's disease in the adult. Ann Rheum Dis. 1971;30:121–33.
- Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;29:424–30.
- Chen DY, Lan JL, Lin FJ, Hsieh TY. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol. 2004;31: 2189–98.
- Scheinberg MA, Chapira E, Fernandes ML, Hubscher 0. Inter-leukin 6: a possible marker of disease activity in adult onset Still's disease. Clin Exp Rheumatol 1992; 653–5.
- Nishimoto N, Kishimoto T, Yoshizaki K. Anti-interleukin 6 receptor antibody treatment in rheumatoid arthritis. Ann Rheum Dis. 2000;59\(suppl 1):i21–7.
- Sato K, Tsuchiya M, Saldanha J, Koishihara Y, Ohsugi Y, Kishimoto T, et al. Reshaping a human antibody to inhibit the interleukin-6-dependent tumor cell growth. Cancer Res. 1993;53: 851–6.
- Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005;52: 818–25.
- Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Liv-ermore P, et al. Open-label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther. 2005;7: R1281–8.
- Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371: 998–1006.
- Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin 6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum. 2002;46:3388–9.
- Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
- Information for proper use of infliximab (in Japanese) by Tanabe Seiyaku. http://medical.tanabe.co.jp/mstaff/remicade/index_ remicade.shtml.
- Saiki 0, Uda H, Nshimoto N, Miwa T, Mima T, Ogawara T, et al. Adult Still's disease reflects a Th2 rather than a Th 1 cytokine profile. Clin Immunol. 2004;112: 120–5.
- Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces proinflammatory and cata-bolic responses. J Immunol. 1999;162:1096–100.
- Jablonska E, Jablonski J. Effect of IL-18 on the release of IL-6 and its soluble receptors: sIL-6Ra and sgp 130 by human neu-trophils. Immunological Investigations. 2002;31:159–67.
- Yamamura M, ICawashima M, Taniai M, Yamauchi H, Tanimoto T, Kurimoto M, et al. Interferon-y-inducing activity of interleu-kin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275–85.